Theralase Technologies Inc.  

(Public, CVE:TLT)   Watch this stock  
Find more results for TLT
+0.015 (5.36%)
Delayed:   1:03PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.28 - 0.30
52 week 0.20 - 0.56
Open 0.29
Vol / Avg. 148,875.00/202,249.00
Mkt cap 24.12M
P/E     -
Div/yield     -
EPS -0.03
Shares 81.76M
Beta 1.01
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -69.23% -95.73%
Operating margin -69.23% -95.73%
EBITD margin - -85.28%
Return on average assets -43.89% -60.36%
Return on average equity -51.51% -135.62%
CDP Score - -


1945 Queen Street East
+1-416-6995273 (Phone)
+1-416-6995250 (Fax)

Website links


Theralase Technologies Inc. designs, develops, manufactures and markets patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: first, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; second, wound care and healing (including non-healing fractures and bone fracture regeneration); and third, research and development into combining patented photodynamic compounds with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses. It focuses on the production, marketing and distribution of the TLC-1000 and TLC-2000 Theralase Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Officers and directors

S. Donald Moore Chairman of the Board
Roger Dumoulin-White President, Chief Executive Officer, Director
Kristina Hachey Chief Financial Officer
Matthew Perraton Director
Guy J. Anderson Independent Director
Randy Bruder Independent Director